MedTrace Logo

Dapagliflozin (DAPA) Effects in HFpEF

NCT04730947 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.

Conditions

Interventions

DRUG

Dapagliflozin

10 mg orally once a day

DRUG

Placebo

Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient

Sponsors & Collaborators

Principal Investigators

  • Barry A Borlaug · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-24
Primary Completion
2022-11-17
Completion
2022-11-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730947 on ClinicalTrials.gov